2001 Cannabinoids Chronic Pain Epilepsy 
Cannabis Law Report
AUGUST 2, 2021
Study Results Indicate SCI-160 Has A Significant Analgesic Effect on Acute and Chronic Pain. Our focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. TEL AVIV, Israel , Aug. 2, 2021 /PRNewswire/ — SciSparc Ltd. About SciSparc (OTCQB: SPRCY ): SciSparc Ltd.
CannaTech
SEPTEMBER 16, 2018
Canada has been at the forefront of shaping much of the rhetoric surrounding cannabis since 2001. But this gap restricts patient access to a medicine that can offer relief to a long list of conditions including chronic pain, seizures attributed to epilepsy, as well as mood disorders such as anxiety and depression.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
OCTOBER 20, 2019
The continued FDA approval of cannabinoid-based medicines is also causing fissures. The pharmaceutical industry would likely have significant opportunities to develop new cannabinoid-based drugs for a multitude of medical conditions now being addressed by medical marijuana. Four of them are now on the market. marijuana companies.
Cannabis Law Report
NOVEMBER 24, 2021
Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Refractory paediatric epilepsy. Cancer pain. Neuropathic pain. Conclusions. 2016 ; Sznitman et al. years (Atakan 2012 ).
Cannabis Law Report
OCTOBER 17, 2019
THC is just one of the cannabinoids in the Cannabis sativa L. The other major cannabinoid of particular interest commercially is cannabidiol (CBD). All told, the global legal cannabis industry, including dried cannabis and products containing cannabinoids, was estimated at US $11.9 The sky’s the limit.
Expert insights. Personalized for you.
105 
Let's personalize your content